Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 12:15 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2449–2472 of 13,471 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Endocrine Disorders Clear all

Conditions: Obstructive Jaundice, Pancreatic Cancer
Interventions: Stent Dysfunction, Complications; Procedure
Lead sponsor: AdventHealth; Other
Eligibility: 19 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Ovarian Cancer, Uterine Cancer
Interventions: Guided imagery and music therapy, White Noise, No intervention; Behavioral · Other
Lead sponsor: University of Minnesota; Other
Eligibility: 19 Years and older · Female only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Achondroplasia
Interventions: BMN 111; Drug
Lead sponsor: BioMarin Pharmaceutical; Industry
Eligibility: 5 Years to 14 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 6
States / cities: Oakland, California • Torrance, California • Chicago, Illinois + 3 more

Conditions: Diabetes Mellitus, Type 2, Diastolic Dysfunction
Interventions: LCZ 696, Placebos; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Diabetes Mellitus, Type 2
Interventions: Placebo, BI 10773; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 499 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 24
States / cities: Muscle Shoals, Alabama • Glendale, Arizona • Phoenix, Arizona + 21 more

Conditions: Type 1 Diabetes Mellitus
Interventions: Microneedle, Subcutaneous insulin catheter; Device
Lead sponsor: Emory University; Other
Eligibility: 8 Years to 18 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Cancer, Carcinoma, Fallopian Tube Cancer, Gynecological Malignancies, Metastases, Oncology, Ovarian Cancer, Solid Tumors, Tumors
Interventions: A1: AMG 386 10 mg/kg + Liposomal doxorubicin, A3: AMG 386 15mg/kg + Liposomal doxorubicin, B1: AMG 386 10 mg/kg + Topotecan, B3: AMG 386 15mg/kg + Topotecan; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 9
States / cities: Tucson, Arizona • Sacramento, California • Orlando, Florida + 6 more

Conditions: Diabetes Mellitus
Interventions: SYR-472, Placebo, Sitagliptin; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 386 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 105
States / cities: Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 102 more

Conditions: Diabetes Mellitus, Food Insecurity
Interventions: Eat Well; Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 2,177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Diabetes
Interventions: Intensive insulin therapy; Drug
Lead sponsor: Hygieia, Inc; Industry
Eligibility: 25 Years to 65 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Paramus, New Jersey

Conditions: Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Interventions: BIBF 1120; Drug
Lead sponsor: AA Secord; Other
Eligibility: 18 Years and older · Female only
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 3
States / cities: Durham, North Carolina • Charlottesville, Virginia • Norfolk, Virginia

Conditions: Diabetes Mellitus, Type 1, Endothelial Dysfunction
Interventions: Dulaglutide, Placebo; Drug
Lead sponsor: AdventHealth Translational Research Institute; Other
Eligibility: 18 Years to 40 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Type 1 Diabetes
Interventions: ORMD-0801 Treatment A, ORMD-0801 Treatment B, Placebo; Drug · Other
Lead sponsor: Oramed, Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Tustin, California

Conditions: Localized Pancreatic Ductal Adenocarcinoma, Stage 0 Pancreatic Cancer AJCC v8, Stage I Pancreatic Cancer AJCC v8, Stage IIA Pancreatic Cancer AJCC v8
Interventions: Interview, Nutritional Therapy, Physical Therapy, Psychosocial Care, Questionnaire Administration; Other · Procedure · Behavioral
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Neoplastic Cells, Circulating, Pancreatic Cancer, Biological Markers
Interventions: No intervention/exposures; Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Type 1 Diabetes Mellitus
Interventions: Dexcom CGM; Device
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 60 Years and older
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 22
States / cities: Beverly Hills, California • La Jolla, California • Aurora, Colorado + 17 more

Conditions: Type 1 Diabetes Mellitus
Interventions: Placebo Oral Tablet, Fluoxetine, DHEA, Fluoxetine and DHEA; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 50 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions: Diabetes Self-Management Training (DSMT), Remote Glucose Monitoring (RGM), Community Health Worker tailored support; Behavioral
Lead sponsor: Sinai Health System; Other
Eligibility: 18 Years and older
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Recurrent Ovarian Cancer
Interventions: CPI-0209, carboplatin; Drug
Lead sponsor: Lan Coffman; Other
Eligibility: 18 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Type 1 Diabetes
Interventions: Normal Glycemia Goal, Tight Glycemia Goal; Device
Lead sponsor: Mark D. DeBoer, MD, MSc., MCR; Other
Eligibility: 6 Years to 13 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 3
States / cities: San Francisco, California • Aurora, Colorado • Charlottesville, Virginia

Conditions: Overweight or Obesity, Prediabetes or Diabetes, Prehypertension (Elevated Blood Pressure) or Hypertension, Resistance Training
Interventions: Resistance Training; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 30 Years to 64 Years · Female only
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Type 2 Diabetes
Interventions: Stable isotope infusion, oral glucose ingestion, intravenous arginine bolus; Other
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 12 Years to 20 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Coronary Artery Disease, Diabetes, Metabolic Syndrome
Interventions: Consume 2 eggs with spinach per day, Egg Subsitute with spinach per day; Other
Lead sponsor: University of Connecticut; Other
Eligibility: 35 Years to 70 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Storrs, Connecticut

Conditions: Pancreatic Cancer, Pancreatic Neoplasms, Adenocarcinoma of the Pancreas
Interventions: 2 passes during EUS-guided fine needle biopsy, 3 passes during EUS-guided fine needle biopsy; Procedure
Lead sponsor: Orlando Health, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Orlando, Florida

Search by objective public record fields.

Trial Comparing Metal Versus Plastic Stents for Preoperative Biliary Decompression

The Effect of Guided Imagery and Music Therapy on Post-Operative Recovery After Gynecological Oncology Surgery

A Phase 2 Study of BMN 111 to Evaluate Safety, Tolerability, and Efficacy in Children With Achondroplasia

PDD in Type 2 Diabetes w/wo Diastolic Dysfunction

Efficacy and Safety of Empagliflozin (BI 10773) in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With Metformin

Insulin Delivery Using Microneedles in Type 1 Diabetes

AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR

Efficacy and Safety of SYR-472 in Subjects With Type 2 Diabetes Mellitus

Eat Well Produce Benefit for Diabetes and Food Insecurity

Efficacy and Safety of Frequently Modified Intensive Insulin

BIBF 1120 in Bevacizumab Resistant, Persistent, or Recurrent Epithelial Ovarian Cancer

Therapeutic Strategies for Microvascular Dysfunction in Type 1 Diabetes

A Study to Compare ORMD-0801 Once Daily to ORMD-0801 Three Times Daily in Subjects With Type 1 Diabetes

A Brief Psychological Intervention to Improve Emotional Well-Being During Neoadjuvant Therapy for Pancreatic Cancer

Changes in Biomarkers From Blood Over Time in Patients With Pancreatic Adenocarcinoma

Wireless Innovation for Seniors With Diabetes Mellitus

The Effects of Fluoxetine and/or DHEA

Improving Diabetes Equity and Advancing Care Study

CPI-0209 Plus Carboplatin in Patients With Platinum Sensitive Recurrent Ovarian Cancer

AIDANET Pediatrics

Remotely Delivered Resistance Training for Cardiometabolic Health Among Black Women

Arginine Metabolism in Youth With Type 2 Diabetes

Benefits of Eggs in Combination With a Plant-based Diet

Randomized Trial for Optimal Number of Passes Required for Molecular Profiling During EUS-FNB of Pancreatic Cancer